Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
GUTS 10.29.2024
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:N/A
About Gravity Analytica
Recent News
- 01.13.2025 - Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
- 12.12.2024 - Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
- 12.09.2024 - Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Recent Filings
BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will report financial results for the third quarter 2024 and provide business updates on Tuesday, November 12, 2024, at 4:30 p.m. ET.
A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website athttps://ir.fractyl.com/. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visitwww.fractyl.comorwww.twitter.com/FractylHealth.
Contacts
Corporate ContactLisa Davidson, Chief Financial Officerir@fractyl.com. 781.902.8800
Media ContactJessica Cotrone, Corporate Communicationsjcotrone@fractyl.com. 978.760.5622
Investor ContactStephen Jasper Gilmartin Groupstephen@gilmartinir.com. 619.949.3681
